This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
The Role Of PD-1 Inhibitors in The Evolving Landscape of Advanced Cutaneous Squamous Cell Carcinoma Treatment

The Role Of PD-1 Inhibitors in The Evolving Landscape of Advanced Cutaneous Squamous Cell Carcinoma Treatment


Expert Perspective

Time to Complete

1 hour


April 15, 2019


April 15, 2020
Add to Queue

Maximum Credits

1.00 / AMA PRA Category 1 CreditTM
1.00 / CNE Contact Hour
1.00 / CE for Pharmacists (0.10 CEUs)

Accredited Provider

CME/CE Credit provided by Advancing Knowledge in Healthcare

Activity is jointly-provided by AKH Inc., Advancing Knowledge in Healthcare and Tarsus Cardio dba South Beach Symposium

Commercial Supporter

This activity is supported by educational grants from Regeneron.

Program Description

Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer after basal cell carcinoma (BCC). The incidence of cSCC in the United States and throughout the world is increasing. In the US, each year 200,000-400,000 new cases of cSCC are expected, with disease-related death occurring in more than 3,000 people with cSCC. Most patients with cSCC are cured with surgery, however, in some patients these tumors can become metastatic or locally advanced and are not cured by surgery or radiation therapy. A large follow-up study of the US population showed that the incidence of invasive cSCC, which may advance or metastasize, increased during an 18-year follow up period. Advanced cSCC is a life-threatening condition, and currently no systemic therapies are approved. Recently, immune checkpoint inhibitors that block the PD-1/PD-L1 pathway have shown promise in the treatment of advanced cSCC. Dermatologists play an important role in the management of cSCC, and their awareness about recent developments in risk stratification, targeted therapies, and follow-up for patients with advanced cSCC is crucial to improve prognosis.

Intended Audience

This activity is designed to meet the needs of Dermatologists, oncologists physician assistants, pharmacists, nurses/nurse practitioners and other health care practitioners who treat SCC.

Educational Objectives

Upon completion of the activity, participants should be better able to:

  • Outline strategies for the identification of high-risk patients with cSCC based on the latest staging systems, risk factors and guidelines
  • Review the mechanisms of action and rationale for the use of PD-1 inhibitors in advanced cSCC
  • Interpret the latest clinical trial data about the efficacy and safety of PD-1 inhibitors in advanced cSCC
  • List the potential dermatologic adverse events resulting from immune checkpoint inhibitor therapy in advanced cSCC, as well as their appropriate management in order to optimize patient outcomes

Conflict Of Interest Disclosure Policy

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review. AKH Inc., Advancing Knowledge in Healthcare, planners and reviewers have no relevant financial relationships to disclose.


Darrell Rigel, MD, MS
Clinical Professor of Dermatology at New York University Medical Center
New York

Dr. Rigel discloses the following:
Advisory Board: Beiersdorf, Inc, Castle Biosciences, Derm Tech International, LEO Pharma, US, Myriad Genetics Inc, Novartis, Ortho Dermatologics, Pierre Fabre Dermo-Cosmetique US
Board of Directors: Foamix
Consultant: Aclaris Therapeutics, Inc.
Contracted Research: Castle Biosciences

David Goldberg, MD, JD
Clinical Professor of Dermatology and Chief of Dermatologic Surgery at UMDNJ
Adjunct Professor of Law
Yale University School of Medicine
New York, NY

Dr. Goldberg discloses the following:
Consultant: Sensus, Zimmer
Contracted Research: Allergan, Galderma, Merz
Speakers Bureau: AdvaLight, Aerolase, Cutera, Lumenis, Neauvia, Sensus, Stratpharma, Wontech, Zimmer

Emily Ruiz, MD
Director of the Dana-Farber/Brigham and Women’s High-Risk Skin Cancer Clinic
Associate Physician at the Mohs and Dermatologic Surgery Center at Dana-Farber/Brigham & Women’s Cancer Center
Instructor at Harvard Medical School

Dr. Ruiz has nothing to disclose.

Accredited Provider Disclosure

AKH has nothing to disclose.

Publishing Staff Disclosures

AKH & SBS have nothing to disclose.




AMA PRA Category 1 Credit(s)TM

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc., Advancing Knowledge in Healthcare and Tarsus Cardio dba South Beach Symposium. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM  .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credit(s)TM   from organizations accredited by ACCME.




CNE Contact Hour(s)

Accreditation Statement

AKH, Inc., Advancing Knowledge in Healthcare is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Designation Statement

This activity is awarded 1.00 Contact Hours.




CE for Pharmacists

Accreditation Statement

AKH Inc., Advancing Knowledge in Healthcare is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Designation Statement

AKH Inc., Advancing Knowledge in Healthcare approves this knowledge‐based activity for 1.00 contact hour (0.10 CEUs). UAN 0077-9999-19-014-H04-P. Initial release: April 15, 2019

Disclosure of Unlabeled Use

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.


To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/Exam History, which you can access at any time.

If you have any questions relating to the accreditation of this activity, please contact: Trish Brignoni,

Privacy Policy


Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue